VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
GANX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
GANXGain Therapeutics, Inc.
$1.98$84M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksGANXQuarterly Cash Flow

Gain Therapeutics, Inc. (GANX) Quarterly Cash Flow Statement

120+ quarters historyFree accessUpdated daily

Gain Therapeutics, Inc. (GANX) quarterly cash flow statement — complete operating, investing & financing history

GANX Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23
Cash from Operations-4.73M-4.62M-4.93M-5.1M-3.82M-3.45M-6.08M-5.76M-3.59M-5.66M-3.97M-5.02M
Operating CF Margin %------------
Operating CF Growth %-23.71%-33.69%18.92%11.42%-6.55%38.97%-53.18%-14.64%14.96%-44.97%-20.6%0.59%
Net Income-5.61M-4.54M-5.28M-5.81M-4.53M-3.77M-4.49M-8.14M-4.01M-4.72M-4.72M-7.69M
Depreciation & Amortization21.3K28.24K22.82K22.33K20.66K21.31K21.64K20.59K20.53K23.59K20.51K20.24K
Stock-Based Compensation0401.67K460K522.02K419.5K359.33K357.5K1.48M190.42K555.06K907.33K1.23M
Deferred Taxes000000000000
Other Non-Cash Items633.97K11.19K10.86K673.29K109.59K553.98K-44.18K-166.13K-200.15K-135.7K-171.11K45.85K
Working Capital Changes225.93K-522.01K-135.75K-507.53K158.78K-621.03K-1.93M1.05M416.81K-1.38M-5.18K1.37M
Change in Receivables000000000000
Change in Inventory000000000000
Change in Payables531.77K-785.26K-949.14K151.65K1.11M-58.07K-1.85M1.48M703.59K-976.79K-46.1K-677.85K
Cash from Investing00000-43.45K-12M3.02M3.14M1.93M3.05M
Capital Expenditures00000-945-1-21.55K0-19-650-3.64K
CapEx % of Revenue------------
Acquisitions000000000000
Investments------------
Other Investing000000000000
Cash from Financing404.32K16.55M7.03M2.47M2.4M2.31M808.68K10.04M-145.8K9.56M134.47K2.2M
Debt Issued (Net)-25.52K-25.02K-25K-24.24K-22.24K-22.78K-23.12K-22.11K-22.87K-22.58K-22.63K-22.25K
Equity Issued (Net)429.85K16.58M7.41M2.49M2.42M2.34M831.79K10.04M157.94K9.58M157.1K2.22M
Dividends Paid000000000000
Share Repurchases000000000000
Other Financing00-353.73K00-1113.57K-280.87K000
Net Change in Cash-4.3M12.03M2.11M-2.37M-1.31M-1.67M-4.88M6.3M-1.15M7.53M-2.05M332.42K
Free Cash Flow-4.73M-4.62M-4.93M-5.1M-3.82M-3.46M-6.08M-5.78M-3.59M-5.66M-3.97M-5.03M
FCF Margin %------------
FCF Growth %-23.71%-33.65%18.92%11.75%-6.55%38.95%-53.15%-14.98%15.18%-44.62%-18.56%1.39%
FCF per Share-0.11-0.14-0.14-0.17-0.13-0.13-0.23-0.30-0.20-0.35-0.31-0.41
FCF Conversion (FCF/Net Income)0.84x1.02x0.93x0.88x0.84x0.92x1.35x0.71x0.89x1.20x0.84x0.65x
Interest Paid000000000000
Taxes Paid000000000000